Advisory Committees: US FDA Standardizing Decisions On When To Vet Applications

 
• By Sue Sutter

Center for Drug Evaluation and Research also is trying to ensure that questions posed at advisory committee meetings are written in clear and consistent language.

Palm trees
Office of New Drugs' Peter Stein wants to shake some trees to find clinicians who manage rare disease patients. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers